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The Possibility of a Selection Process
in the Ashkenazi Jewish Population
To the Editor:
In a recent article, Risch et al. (2003) analyzed the fre-
quencies of the various inherited disorders that are found
in relatively high frequency among Ashkenazi Jews. By
comparing three parameters—namely, the numbers of
allelic mutations, allele frequency distribution, and esti-
mated coalescence dates of mutations—Risch et al. (2003)
demonstrated a similar pattern of these parameters be-
tween lysosomal storage disorders (LSDs) and 14 preva-
lent nonlysosomal disorders (NLSDs) that are prevalent
among Ashkenazi Jews. Their conclusion, therefore, was
that the LSDs are not unique in this population and the
relatively high prevalence of LSDs stems from a genetic
drift, rather than a selection process in favor of the LSDs
in this population, as suggested elsewhere (Zlotogora et
al. 1988). However, although we agree on the importance
of the genetic drift to explain the high frequency of mu-
tation in the Ashkenazi Jewish population, we still think
that selective advantage for carriers of LSDs was appar-
ently another important factor.
Among 110,000 established gene loci (MIM Statistics,
March 2003), 120 are responsible for disorders found
with an increased prevalence among Ashkenazi Jews. As
expected in a random process, there is no known rela-
tionship between most of the genes responsible for these
disorders. The exceptions are the four prevalent LSDs
among Ashkenazim—namely, Tay-Sachs disease (TSD
[MIM 272800]), Gaucher disease (GD1 [MIM 230800]),
Niemann-Pick disease (NPD [MIM 257200]), and mu-
colipidosis type IV (MLIV [MIM 252650])—in which
the mutations are in genes that encode for enzymes from
a common biochemical pathway. In all cases, the main
storage substances are sphingolipids: GM2 ganglioside
in TSD, glucosylceramide in GD, sphingomyelin in NPD,
and various gangliosides in MLIV. A further indication
of a nonrandom process is the number of mutations
responsible for each disorder. As expected for random
events, in almost all the NLSDs, one mutation is preva-
lent, and, if more than one mutation is found, its fre-
quency is significantly !10% of the first mutation. This
is true for almost all the NLSDs, except cystic fibrosis
(CF [MIM 219700]), where a selection process has been
suggested, and factor 11 deficiency (PTA [MIM 264900]).
On the other hand, in all four LSDs among Ashkenazim,
the second allele is 110% prevalent, when compared
with the frequency of the major mutation. For instance,
in NPD, three mutations are found in equal frequencies,
and, in MLIV, there are two common mutations with a
ratio of ∼2:1. In TSD, the ratio of the three common
mutations is 73:18:3.5. In GD, the ratio between the two
common mutations is 77:13 (Zlotogora et al. 2000).
Furthermore, it should be noted that the data for allelic
frequencies in the Risch et al. (2003) paper was partially
based on the frequencies obtained by the Dor Yeshorim
screening program, which uses mutation analysis. That
program is aimed at the detection of heterozygotes for
some eight prevalent severe disorders among Ashkenazim
and is designed for a specific section of that population,
the ultraorthodox community. We have shown elsewhere
(Bach et al. 2001) that the frequency of TSD and allelic
distribution of the three common mutations, in a sample
of 32,000 individuals in the Dor Yeshorim program, is
significantly different from the distribution found in the
Ashkenazi population at large. We have seen a similar
trend with other disorders as well, including familial dy-
sautonomy (FD [MIM 223900]), MLIV, and others (G.
Bach, unpublished data). Indeed, this community rep-
resents a relatively close section in which most individ-
uals originated from specific locations in Europe. Thus,
the data for allelic distribution in the Ashkenazi popu-
lation, as reported in the article (Risch et al. 2003), does
not fully represent the true picture.
Risch et al. (2003) demonstrated a diverse geographic
distribution of allelic mutations in some of the Ashke-
nazim with LSDs; certain mutations originated in Cen-
tral Europe, whereas others originated in Eastern Europe.
We suggest that this does not contradict a selection pro-
cess, but that it may point to a secondary genetic drift.
A well-known selection process by malaria in favor of
heterozygotes has been demonstrated for sickle cell
anemia (HBB [MIM 603903]) and is suspected for
other blood disorders, such as thalassemia (HBB [MIM
141900]). If we focus on b thalassemia as an example,
many mutations have been described in the populations
that were exposed to malaria for centuries. Comparing
the allelic distribution among Jews who originated from
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a relatively small geographic region, the mutations were
significantly different in the Iranian, Turkish, and Iraqi
parts of the Kurdistan Mountains (Rund et al. 1991).
Nowadays, the high prevalence of thalassemia among
the Kurdish Jews in Israel is due to several mutations,
as a result of two processes: selection and genetic drift.
Determining the forces that led to the present observa-
tions in the Ashkenazi Jews is complicated, and there is
no clear data for the nature of the selection process in
favor of the carriers of LSDs, if that process occurred.
It was suggested that certain lung disorders (i.e., pneu-
monia and tuberculosis) conferred a heterozygous ad-
vantage for these disorders (Myrianthopoulos and Mel-
nick 1977). If this is indeed the basis for the selection
phenomenon or, in fact, any other similar environmental
factor, the occurrence of different geographic origins of
the various allelic mutations or different coalescence
dates does not contradict a selection process but, rather,
strengthens it. Regarding Ashkenazi Jews, although we
have no clear evidence for the selection force, we can
safely assume that the environmental factor lasted for
centuries and that there is no reason to doubt that this
selection force was effective in Central Europe as well
as in the eastern part. Medical care for the Jewish people
was not basically different in these regions. Thus, we
would expect to find diverse distributions of allelic mu-
tations for a selection process. Although the four LSDs
are recessive, it can be postulated that, under extreme
conditions, such as lung disorders, heterozygotes might
undergo even a slight lysosomal storage of these sub-
stances, which might confer beneficial resistance to these
conditions.
To try to understand the past, one can look at the
present and foresee the future. This can be done for
genetic diseases found nowadays in populations whose
living conditions are similar to those of the Ashkenazi
Jews in Europe. One example is the Arab population
living in the Middle East, in which the preference is for
consanguineous marriages, as was the case for the Ash-
kenazi Jews. For the Jews who lived in Europe, like the
Arabs living nowadays in Israel, further reasons to marry
within the community were religious and geopolitical.
In these populations, many genetic diseases are found
with a high prevalence, and, although most are due to
a single random mutation, others present a different
distribution.
For instance, among Arabs in Galilee, several diseases
are found with an increased prevalence. On a molecular
basis, in most cases, a single founder mutation explains
the relatively high frequency for each disease. However,
for other diseases—such as metachromatic leukodystro-
phy (MLD [MIM 250100]), Hurler syndrome (MPS1
[MIM 252800]), hyperoxaluria (HP1 [MIM 259900]),
or ataxia telangiectasia (AT [MIM 208900])—many dif-
ferent mutations were found (Zlotogora 2002). In each
case, all the patients were homozygous for a single mu-
tation that was frequent, in general, in one village only.
Another example is the high frequency of Mendelian
disorders among the Bedouins of the Negev, owing to, in
most cases, random founder mutations (Sheffield et al.
1998). However, Bardet-Biedl syndrome (BBS [MIM
209900]) is present among the Bedouins of the Negev
in a very high prevalence, owing to mutations in three
different genes. These observations, of either several mu-
tations in the same gene or mutations in different genes
responsible for the high prevalence of some genetic dis-
eases in relatively small populations, cannot be explained
as a random phenomenon. The possibility of a selective
phenomenon must be raised, even though it has not yet
been characterized. It may be expected that, in the fu-
ture, with the expansion and mixing of the population,
some of these mutations will be lost, whereas others will
remain. Some mutations that are the result of genetic drift
will be relatively prevalent in the general Arab population.
One may wonder why the selection phenomenon was
restricted primarily to the Ashkenazim and not to the
non-Jewish people around them. Two, equally plausible,
assumptions might explain this phenomenon. (a) The
Jews in Europe, particularly in earlier periods (i.e., the
10th–17th centuries) lived for the most part in an ex-
tremely poor socioeconomic status with poor medical
management. Thus, a selection force by heterozygous
advantage might have been more effective for that pop-
ulation. (b) The genetic background of Jews was shown
to be unique and different from that of other European
people. It can be postulated that this particular genetic
structure might have conferred a higher sensitivity or
susceptibility to certain lung disorders, when compared
with other people in the same region.
We, therefore, conclude that the LSDs among Ashke-
nazim represent a unique group indicating a nonrandom
phenomenon that might be explained by a selection pro-
cess. This does not contradict a genetic drift, as was in-
dicated by Risch et al. (2003)
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Selection in the Ashkenazi Jewish Population
Unlikely—Reply to Zlotogora and Bach
To the Editor:
Zlotogora and Bach (2003 [in this issue]) raise a number
of issues that argue for distinctiveness of the lysosomal
storage diseases (LSDs) versus the nonlysosomal storage
diseases (NLSDs). They note that the four LSDs involve
a similar biochemical pathway. However, our list of
NLSDs also includes three tumor-suppressor genes—
breast cancer type 1 (BRCA1 [MIM 113705]), breast
cancer type 2 (BRCA2 [MIM 600185]), and adenom-
atous polyposis of the colon (APC [MIM 175100])—and
a similar argument could be applied to these. Other pop-
ulations experiencing founder effects also show such pat-
terns. For example, the European Romani population
demonstrates founder effects for three different sensory
neuropathy syndromes (Kalaydjieva et al. 2001). An al-
ternative explanation to heterozygote advantage is de-
tection bias—namely, the recognition of one or two LSDs
in the Ashkenazi Jewish population focused greater at-
tention on the identification of others. For example, it is
likely that additional cancer mutations will also be iden-
tified in the Ashkenazi Jewish population.
Zlotogora and Bach (2003 [in this issue]) suggest that
the number of mutations differs between the LSDs and
NLSDs, with the LSDs having a higher frequency of sec-
ondary mutations. However, our table 1 (Risch et al.
2003) shows this not to be the case. The maximum fre-
quencies for secondary mutations for LSDs are .003, for
Tay-Sachs disease (TSD [MIM 272800]) (mutation 1421),
and .002, for Gaucher disease (GD [MIM 230800]) (mu-
tation 84GG). Secondary mutations with frequencies
as high or higher also exist for factor 11 deficiency (F11
[MIM 264900]), connexin 26 (CX26 [MIM 121011]),
Canavan disease (CAN [MIM 271900]), and cystic fi-
brosis (CF [MIM 219700]). In addition, breast cancer
type 1 (BRCA1 [MIM 113705]) and hyperinsulinism (HI
[MIM 256450]) also have secondary mutations in this
frequency range. There is no difference in number and
frequency distribution for the second-most-frequent mu-
tations between the LSDs and NLSDs. The data in table
1 that we used for this analysis were derived entirely
from the literature and not from Dor Yeshorim and thus
should be representative of the Ashkenazi Jewish popu-
lation generally. The Dor Yeshorim database was used
only for the geographic analyses presented in tables 4 and
5 (Risch et al. 2003). In fact, we showed that it is because
the Dor Yeshorim population derives a greater proportion
of ancestry from Central Europe, versus Eastern Europe,
that its frequency ratio for TSD mutation 1277 versus
mutation 1421 differs from other Ashkenazi Jewish
samples.
The b thalassemia (MIM 141900) example described
by Zlotogora and Bach (2003 [in this issue]) provides a
useful point of discussion. For b thalassemia, a recessive
lethal disease, various mutations have been found at ex-
cessively high frequency (much higher than any reported
in Ashkenazi Jews, as given in our table 1 [Risch et al.
2003]) and in various populations that had been histor-
ically exposed to malaria. The same applies to glucose-
6-phosphate dehydrogenase (G6PD) deficiency (MIM
305900). This is the opposite of the pattern observed for
the LSDs in the Ashkenazim. These diseases are not in-
creased in frequency in any group living historically in
neighboring locales with shared environmental exposures,
even over centuries. Despite potential economic differ-
ences, it seems unlikely that prevalent diseases would not
also have an impact on non-Jews; also, except for founder
mutations, the Ashkenazi population is not that different
